Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) set October 27, 2025 as the record date to distribute contingent value rights (CVRs) to holders of its Class B subordinate voting shares on a one-for-one basis. Each CVR entitles holders to a pro rata share of a minimum of 10% and up to 50% of the net proceeds the company ultimately recovers from its litigation alleging stock price manipulation and spoofing, which seeks damages in excess of USD $700 million. No payments will be made unless and until the company receives Qualifying Net Proceeds following a settlement or a final, non-appealable judgment. The CVRs will be non-transferable, unlisted, non-voting, non-interest bearing, redeemable only for cash upon receipt of Qualifying Net Proceeds, and the distribution date remains undetermined.
Quantum BioPharma (NASDAQ: QNTM) has reached a significant milestone in the development of Lucid-21-302 (Lucid-MS), its potential breakthrough drug for Multiple Sclerosis. The company received final reports for two critical studies: the 90-day oral toxicity study and the toxicokinetic study.
These reports will support Quantum's Investigational New Drug (IND) application to the US FDA for a planned Phase 2 clinical trial. Lucid-MS is being developed as a first-in-class treatment targeting demyelination in Multiple Sclerosis patients.
Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Dr. Jack Antel, a world-renowned multiple sclerosis expert, as clinical advisor for its MS program focused on Lucid-21-302 (Lucid-MS). Dr. Antel will advise on the clinical development and efficacy trial design for Lucid-MS, a patented investigational drug designed to inhibit demyelination in MS.
Dr. Antel brings significant expertise as a Professor of Neurology at McGill University and former National Scientific Director of the endMS Research and Training Network. He has published over 450 scientific articles and held prestigious positions including Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada and President of ACTRIMS.
He will join existing advisor Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, to support Quantum's development of Lucid-MS toward Phase 2 clinical trials.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, held its annual general and special meeting of shareholders on September 26, 2025. The meeting saw strong participation with 100% of Class A Multiple Voting Shares and 46.352% of Class B Subordinate Voting Shares represented.
All seven nominated directors were successfully elected with over 99.6% approval rates. Shareholders also approved the re-appointment of MNP LLP as auditor with 99.588% support and authorized the potential issuance of up to 56 additional Class A Multiple Voting Shares, receiving 90.992% approval from eligible Class B shareholders.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, has announced key corporate updates regarding equity compensation. The Board approved the grant of 32,000 restricted share units (RSUs) to three key executives, which will vest upon completion of Phase 2 MS Study data compilation.
Additionally, the company granted 98,000 stock options to directors, officers, employees, and consultants at C$24.50 per Class B Share, with immediate vesting and expiration on September 24, 2030. Both grants are subject to a four-month statutory hold period and constitute related party transactions under MI 61-101, though qualifying for exemptions from formal valuation and minority shareholder approval requirements.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 1, 2025 at 4:30 PM EST to discuss its Regulation D 506(c) offering aiming to raise up to $5 million.
The webinar will feature presentations from key executives including CEO John Duffy, discussing Unbuzzd's clinically proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company plans to use the funds for direct-to-consumer expansion, distributor and retail growth, and to establish a path toward a potential IPO. Importantly, Quantum BioPharma shareholders will not face dilution from this offering.
Quantum BioPharma (NASDAQ: QNTM) has received a Product License (PN 80144141) from Health Canada for Qlarity™, its innovative natural health product. The license allows Quantum to market Qlarity in Canada with approved claims for enhancing energy production, metabolism, mental alertness, and cognitive performance.
The company has already licensed a similar product in the United States under the brand name unbuzzd™. This regulatory approval marks a significant milestone in Quantum's strategy to expand its portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on September 16, 2025, at 1:30 PM PT. The webinar will feature presentations from key executives including CEO John Duffy, discussing their scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms.
The webinar will focus on Unbuzzd's Regulation D 506(c) offering aiming to raise up to $5.0 million to support expansion plans and a possible IPO. Company leaders will present clinical study results, growth strategies, and plans for direct-to-consumer, distributor, and retail sales. Importantly, Quantum BioPharma shareholders will not face dilution from this offering.
Quantum BioPharma (NASDAQ: QNTM) has received analyst coverage initiation from Kingswood Capital Partners with a BUY rating and US$45 price target. The valuation is based on a discounted cash flow analysis assuming successful Phase 2 and 3 trials of Lucid-MS during 2026-2028, with anticipated commercial launch in 2029.
The coverage is led by Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners. Notably, this is unpaid research with no consideration provided by Quantum BioPharma, which is developing innovative solutions for neurodegenerative, metabolic, and alcohol misuse disorders.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced several corporate updates. The company settled $26,812.50 USD in debt through the issuance of 1,102 Class B Shares at $24.33 USD per share.
The Board granted 800 RSUs each to Clinical Advisors Peter Stys and Jack Antel, with vesting tied to regulatory milestones for Lucid MS clinical trials. Additionally, Kevin Malone's Board Advisor Agreement was terminated effective August 15, 2025.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
